Download PDFPDF

1368 A novel bispecific BCA356 targeting tumour antigen CAIX conjugated to an attenuated IL12 demonstrates pre-clinical efficacy with potential for limited systemic toxicity
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address